RECRUITING: Bionetide (NA-921) trial – Australia and USA

[admin]

Status: RecruitingStudy: Oral NA-921 (Bionetide) versus placebo
Registry number: NCT06840496
Countries: Australia and United States
Participants: Females aged 5–20 years

What is being studied?
This study is assessing whether oral Bionetide improves Rett symptoms, including communication, compared with placebo. Participants must have typical/classic Rett syndrome and a documented disease-causing MECP2 variant.

Australian locations include Camperdown, South Brisbane, Heidelberg West and Parkville. US locations include sites in Arizona, California, Colorado, Florida, Illinois, Maryland, Massachusetts, New York, Pennsylvania, Texas and Washington.

Contact: research@biomedind.com — +1 800 824 5135
Official study record: https://clinicaltrials.gov/study/NCT06840496

Information checked 3 September 2026. Registry status and eligibility can change. Please contact the study team and consult the person’s clinical team before considering participation.